275 results on '"Manolopoulos, V.G."'
Search Results
2. Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population
- Author
-
Tavridou, A., Arvanitidis, K.I., Tiptiri-Kourpeti, A., Petridis, I., Ragia, G., Kyroglou, S., Christakidis, D., and Manolopoulos, V.G.
- Published
- 2009
- Full Text
- View/download PDF
3. Characterisation of explanted endothelial cells from mouse aorta: electrophysiology and Ca2+ signalling
- Author
-
Suh, S.H., Vennekens, R., Manolopoulos, V.G., Freichel, M., Schweig, U., Prenen, J., Flockerzi, V., Droogmans, G., and Nilius, B.
- Published
- 1999
- Full Text
- View/download PDF
4. Personalized Medicine
- Author
-
Gurwitz, D., primary and Manolopoulos, V.G., additional
- Published
- 2007
- Full Text
- View/download PDF
5. Association study of the CTH 1364 G>T polymorphism with coronary artery disease in the Greek population
- Author
-
Giannakopoulou, E. Konstantinou, F. Ragia, G. Gerontitis, Z. Tavridou, A. Papapetropoulos, A. Mikroulis, D. Manolopoulos, V.G.
- Abstract
Cystathionine γ-lyase enzyme, which is encoded by the CTH gene, is responsible for hydrogen sulfide (H2S) production in the endothelium. The CTH 1364 G>T polymorphism may alter the CTH expression and H2S bioavailability, thus leading to atherosclerosis and coronary artery disease (CAD). We examined the potential association of the CTH 1364 G>T polymorphism with CAD. The CTH 1364 G>T polymorphism was determined in 178 coronary artery bypass grafting (CABG) patients and 156 non-atherosclerotic controls of Greek Caucasian origin using the PCR-RFLP method. No significant difference in the frequency of the CTH 1364 G>T genotypes (p = 0.281) and alleles (p = 0.265) was found between the CABG patients and controls. After conducting stratification according to sex, analysis showed a numerical difference in the CTH 1364 TT genotype frequency in female participants that did not reach statistical significance (16.3% and 8.5% in the CABG and controls, respectively, p = 0.26). The frequency of the CTH 1364 TT genotype between the male CABG patients and controls did not differ (p = 0.507). The CTH 1364 G>T polymorphism was not associated with CAD in the studied population. However, interestingly, a higher - if not significantly so - CTH 1364 TT genotype frequency was present in female CABG patients compared with female controls. Larger studies are necessary to conclude on the potential overall or gender-driven association between CTH 1364 G>T gene polymorphism and CAD. © 2019 Walter de Gruyter GmbH, Berlin/Boston.
- Published
- 2019
6. The European Association for Clinical Pharmacology and Therapeutics-25 years' young and going strong
- Author
-
Coleman, J.J., Samer, C., Zeitlinger, M., Agtmael, M. van, Rongen, G.A.P.J.M., Marquet, P., Simon, T., Singer, D., Manolopoulos, V.G., Bottiger, Y., Coleman, J.J., Samer, C., Zeitlinger, M., Agtmael, M. van, Rongen, G.A.P.J.M., Marquet, P., Simon, T., Singer, D., Manolopoulos, V.G., and Bottiger, Y.
- Abstract
Contains fulltext : 205530.pdf (publisher's version ) (Open Access), Clinical pharmacology as a scientific discipline and medical specialty was unarguably born in the twentieth century. Whilst pharmacology-the science behind the treatment of disease-had been in evolution since at least medieval times, the clinical discipline of pharmacology has had a more recent genesis and rather insidious evolution. During the 1900s, there were some clear father (parent) figures of clinical pharmacology in Europe that emerged and were responsible for the development of the specialty in this continent. This was a time when there were parallel developments in geographically dispersed academic departments (around the globe), during an age of excitement in drug discovery and clinical application of new therapeutic agents. It was the meeting of minds of some of these progenitors of the specialty that led to the development of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 25 years ago arising from a working party supported by the World Health Organization in Europe. The EACPT now includes all major national organizations for clinical pharmacology in Europe, representing over 4000 individual professionals interested in clinical pharmacology and therapeutics. The EACPT has a major interest in promoting the safe use of medicines across Europe and internationally and has supported these aims since 1995, through biennial international scientific congresses and summer schools with delegates and presenters from around the world as well as various working group activities. In this article, the current executive committee members of EACPT recall this history, describe the evolution of the association over the last quarter of a century, and provide an update on the activities and ambitions of the association today.
- Published
- 2019
7. 4th ESPT summer school: precision medicine and personalised health
- Author
-
Mlakar, V., Marc, J. (Janja), Manolopoulos, V.G. (Vangelis), Cascorbi, I., Stankovic, S., Llerena, A. (Adrián), Simmaco, M, Visvikis-Siest, S. (Sophie), Amstutz, U., Sipeky, C., Meyer, U. A., Meier-Abt, P., Schaik, R.H.N. (Ron) van, Ansari, M. (Morad), Mlakar, V., Marc, J. (Janja), Manolopoulos, V.G. (Vangelis), Cascorbi, I., Stankovic, S., Llerena, A. (Adrián), Simmaco, M, Visvikis-Siest, S. (Sophie), Amstutz, U., Sipeky, C., Meyer, U. A., Meier-Abt, P., Schaik, R.H.N. (Ron) van, and Ansari, M. (Morad)
- Published
- 2019
- Full Text
- View/download PDF
8. Pharmacogenomics education in medical and pharmacy schools: Conclusions of a global survey
- Author
-
Karas Kuželički, N. (Nataša), Prodan Žitnik, I. (Irena), Gurwitz, D. (David), Llerena, A. (Adrián), Cascorbi, I. (Ingolf), Siest, S. (Sofia), Simmaco, M. (Maurizio), Ansari, M. (Marc), Pazzagli, M. (Mario), Di Resta, C. (Chiara), Brandslund, I. (Ivan), Schwab, M. (Matthias), Vermeersch, P. (Paul), Lunshof, J.E. (Jeantine E.), Dedoussis, G.V. (George), Flordellis, C.S. (Christodoulos S.), Fuhr, U. (Uwe), Stingl, J. (Julia), Schaik, R.H.N. (Ron) van, Manolopoulos, V.G. (Vangelis), Marc, J. (Janja), Karas Kuželički, N. (Nataša), Prodan Žitnik, I. (Irena), Gurwitz, D. (David), Llerena, A. (Adrián), Cascorbi, I. (Ingolf), Siest, S. (Sofia), Simmaco, M. (Maurizio), Ansari, M. (Marc), Pazzagli, M. (Mario), Di Resta, C. (Chiara), Brandslund, I. (Ivan), Schwab, M. (Matthias), Vermeersch, P. (Paul), Lunshof, J.E. (Jeantine E.), Dedoussis, G.V. (George), Flordellis, C.S. (Christodoulos S.), Fuhr, U. (Uwe), Stingl, J. (Julia), Schaik, R.H.N. (Ron) van, Manolopoulos, V.G. (Vangelis), and Marc, J. (Janja)
- Abstract
Aim: The need for pharmacogenomic education is becoming more and more urgent. Our aim was to evaluate the progress in pharmacogenomics education since then, and to put forward further recommendations. Methods: A survey was sent to 248 schools of medicine, pharmacy, nursing and health professions around the world. Results: The majority of the study programs (87%) include pharmacogenomics education, which is generally taught as part of the pharmacology curriculum. On average, educators and teachers have selected appropriate and highly relevant pharmacogenomics biomarkers to include in their teaching programs. Conclusions: Based on the results, we can conclude that the state of pharmacogenomics education at the surveyed universities has improved substantially since 2005.
- Published
- 2019
- Full Text
- View/download PDF
9. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes
- Author
-
Baranova, E.V., Verhoef, T.I., Ragia, G., le Cessie, S., Asselbergs, F.W., de Boer, A., Manolopoulos, V.G., Maitland‐van der Zee, A.H., Barallon, R., Daly, A., Kamili, F., Redekop, K., Pirmohamed, M., Rosendaal, F.R., and Wadelius, M.
- Published
- 2017
- Full Text
- View/download PDF
10. Epigenetics-by-Sex Interaction for Coronary Artery Disease Risk Conferred by the Cystathionine γ-Lyase Gene Promoter Methylation
- Author
-
Giannakopoulou, E. Konstantinou, F. Ragia, G. Tavridou, A. Karaglani, M. Chatzaki, E. Papapetropoulos, A. Mikroulis, D. Manolopoulos, V.G.
- Abstract
Coronary artery disease (CAD) is a major global health burden whereby gene-by-environment-by-sex interactions play an important role. Coronary artery bypass graft (CABG) surgery involves patients with well-documented and severe CAD. Hence, the study of CAD in a context of the CABG surgery serves as an advantageous model for disease phenotype ascertainment and genetic association studies. We report here new observations from a case-control genetic association study on promoter methylation of the cystathionine γ-lyase (CTH) gene and its association with CAD. To the best of our knowledge, this is the first clinical study to show the DNA methylation status of the CTH promoter in relation to this clinical phenotype. CTH encodes for the hydrogen sulfide generating enzyme named CSE in the endothelium that is mechanistically highly relevant for CAD. In a sample of 334 subjects from Greece (178 cases with CAD and who underwent CABG, and 156 controls), CTH promoter methylation was analyzed using a SYBR Green-based quantitative methylation-specific polymerase chain reaction. We found increased methylation in CTH promoter in cases (19.1%) compared to controls (10.3%) (p = 0.024). Gene-by-sex analysis sustained the significant association in men (p = 0.032) but not in women (p = 0.884). By using multivariate analyses after controlling for potential confounders such as smoking, age, and gender, we found that increased CTH gene promoter methylation was associated with CAD in the total sample (odds ratio [OR] = 2.163, 95% confidence interval [CI] 1.038-4.506, p = 0.039) and in men (OR = 2.418, 95% CI 1.048-5.581, p = 0.039) but not in women (OR = 0.542, 95% CI 0.094-3.140, p = 0.495). These observations collectively warrant further precision medicine and biomarker research to examine the CTH methylation status as a putative epigenetic regulator of CAD risk in larger and independent samples. © Copyright 2017, Mary Ann Liebert, Inc.
- Published
- 2017
11. Age-Stratified Outcome Of Genotype-Guided Dosing Algorithm For Acenocoumarol And Phenprocoumon
- Author
-
Zhang, Y., Boer, A. de, Verhoef, T.I., Meer, F.J.M. van der, Cessie, S. le, Manolopoulos, V.G., and Maitland-Van Der Zee, A.H.
- Published
- 2016
12. Cardioprotection by H2S Donors: Nitric Oxide-Dependent and -Independent Mechanisms
- Author
-
Chatzianastasiou, A. Bibli, S.-I. Andreadou, I. Efentakis, P. Kaludercic, N. Wood, M.E. Whiteman, M. Lisa, F.D. Daiber, A. Manolopoulos, V.G. Szabó, C. Papapetropoulos, D.A.
- Abstract
Hydrogen sulfide (H2S) is a signaling molecule with protective effects in the cardiovascular system. To harness the therapeutic potential of H2S, a number of donors have been developed. The present study compares the cardioprotective actions of representative H2S donors from different classes and studies their mechanisms of action inmyocardial injury in vitro and in vivo. Exposure of cardiomyocytes to H2O2 led to significant cytotoxicity, which was inhibited by sodium sulfide (Na2S), thiovaline (TV), GYY4137 [morpholin-4-ium 4 methoxyphenyl(morpholino) phosphinodithioate], and AP39 [(10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol5yl)- phenoxy)decyl) triphenylphospho-nium bromide]. Inhibition of nitric oxide (NO) synthesis prevented the cytoprotective effects of Na2S and TV, but not GYY4137 and AP39, against H2O2-induced cardiomyocyte injury. Mice subjected to left anterior descending coronary ligation were protected from ischemia-reperfusion injury by the H2S donors tested. Inhibition of nitric oxide synthase (NOS) in vivo blocked only the beneficial effect of Na2S. Moreover, Na2S, but not AP39, administration enhanced the phosphorylation of endothelial NOS and vasodilator-associated phosphoprotein. Both Na2S and AP39 reduced infarct size in mice lacking cyclophilin-D (CypD), a modulator of the mitochondrial permeability transition pore (PTP). Nevertheless, only AP39 displayed a direct effect on mitochondria by increasing the mitochondrial Ca2+ retention capacity, which is evidence of decreased propensity to undergo permeability transition. We conclude that although all the H2S donors we tested limited infarct size, the pathways involved were not conserved. Na2S had no direct effects on PTP opening, and its action was nitric oxide dependent. In contrast, the cardioprotection exhibited by AP39 could result from a direct inhibitory effect on PTP acting at a site different than CypD. Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.
- Published
- 2016
13. POR∗28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia
- Author
-
Drogari, E. Ragia, G. Mollaki, V. Elens, L. Van Schaik, R.H. Manolopoulos, V.G.
- Abstract
Background: In children and adolescents with familial hypercholesterolemia (FH) pharmacotherapy with statins is the cornerstone in the current regimen to reduce low-density lipoprotein cholesterol (LDLc) and premature coronary heart disease risk. There is, however, a great interindividual variation in response to therapy, partially attributed to genetic factors. The polymorphic enzyme POR transfers electrons from NADPH to CYP450 enzymes including CYP3A, which metabolize atorvastatin. POR∗28 polymorphism is associated with increased CYP3A enzyme activity. We analyzed the association of POR∗28 allele with response to atorvastatin. Materials & methods: One hundred and five FH children and adolescents treated with atorvastatin at doses 10-40 mg were included in the study. Total cholesterol (TChol) and LDLc were measured at baseline and after 6 months of treatment. POR∗28 allele was analyzed with TaqMan assay. CYP3A4∗22, CYP3A5∗3 and SLCO1B1 521T>C and 388A>G genotypes were also determined with TaqMan or PCR-RFLP methods. Results: POR∗28 carriers had significantly lower percent mean reduction of TChol (33.1% in ∗1/∗1, 29.8% in ∗1/∗28 and 25.9% in ∗28/∗28 individuals, p = 0.045) and of LDLc (43.9% in ∗1/∗1, 40.9% in ∗1/∗28 and 30.8% in ∗28/∗28 individuals, p = 0.013). In multivariable linear regression adjusted for confounding factors, POR∗28 genotypes, additionally to baseline cholesterol level, accounted for an estimated 8.3% and 7.3% of overall variability in % TChol and LDLc reduction (β: 4.05; 95% CI: 1.73-6.37; p = 0.001 and β: 5.08; 95% CI: 1.62-8.54; p = 0.004, respectively). CYP3A4∗22, CYP3A5∗3 and SLCO1B1 521T>C and 388A>G polymorphisms were not associated with lipid reductions and did not modify the effect of POR∗28 on atorvastatin response. Conclusion: In children with FH, carriage of POR∗28 allele is associated with reduced effect of atorvastatin on TChol and LDLc and therefore identifies FH children that may require higher atorvastatin doses to achieve full therapeutic benefits. Additional studies in different populations are needed to replicate this association. © 2014 Future Medicine Ltd.
- Published
- 2014
14. Systems medicine, personalized health and therapy
- Author
-
Siest, G., Auffray, C., Taniguchi, N., Ingelman-Sundberg, M., Murray, H., Visvikis-Siest, S., Ansari, M., Marc, J., Jacobs, P., Meyer, U., Schaik, R.H. van, Müller, M.M., Wevers, R.A., Simmaco, M., Kussmann, M., Manolopoulos, V.G., Alizadeh, B.Z., Beastall, G., Németh, G., Siest, G., Auffray, C., Taniguchi, N., Ingelman-Sundberg, M., Murray, H., Visvikis-Siest, S., Ansari, M., Marc, J., Jacobs, P., Meyer, U., Schaik, R.H. van, Müller, M.M., Wevers, R.A., Simmaco, M., Kussmann, M., Manolopoulos, V.G., Alizadeh, B.Z., Beastall, G., and Németh, G.
- Abstract
Item does not contain fulltext
- Published
- 2015
15. A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon
- Author
-
Verhoef, T.I., Ragia, G., Boer, A. de, Barallon, R., Kolovou, G., Kolovou, V., Konstantinides, S., Cessie, S. le, Maltezos, E., Meer, F.J.M. van der, Redekop, W.K., Remkes, M., Rosendaal, F.R., Schie, R.M.F. van, Tavridou, A., Tziakas, D., Wadelius, M., Manolopoulos, V.G., Maitland-van der Zee, A.H., EU-PACT Grp, Pulmonology, APH - Amsterdam Public Health, Epidemiology and Data Science, Cardiology, and Health Economics (HE)
- Subjects
Male ,medicine.medical_specialty ,Genotype ,030204 cardiovascular system & hematology ,law.invention ,Phenprocoumon ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Thromboembolism ,Vitamin K Epoxide Reductases ,medicine ,Humans ,Single-Blind Method ,Dosing ,International Normalized Ratio ,Treatment Failure ,CYP2C9 ,Aged ,Cytochrome P-450 CYP2C9 ,Acenocoumarol ,business.industry ,Incidence (epidemiology) ,Anticoagulants ,Atrial fibrillation ,General Medicine ,Middle Aged ,medicine.disease ,3. Good health ,Surgery ,Pharmacogenetics ,030220 oncology & carcinogenesis ,Female ,VKORC1 ,Aryl Hydrocarbon Hydroxylases ,business ,Algorithms ,medicine.drug ,Follow-Up Studies - Abstract
BACKGROUND Observational evidence suggests that the use of a genotype-guided dosing algorithm may increase the effectiveness and safety of acenocoumarol and phenprocoumon therapy. METHODS We conducted two single-blind, randomized trials comparing a genotype-guided dosing algorithm that included clinical variables and genotyping for CYP2C9 and VKORC1 with a dosing algorithm that included only clinical variables, for the initiation of acenocoumarol or phenprocoumon treatment in patients with atrial fibrillation or venous thromboembolism. The primary outcome was the percentage of time in the target range for the international normalized ratio (INR; target range, 2.0 to 3.0) in the 12-week period after the initiation of therapy. Owing to low enrollment, the two trials were combined for analysis. The primary outcome was assessed in patients who remained in the trial for at least 10 weeks. RESULTS A total of 548 patients were enrolled (273 patients in the genotype-guided group and 275 in the control group). The follow-up was at least 10 weeks for 239 patients in the genotype-guided group and 245 in the control group. The percentage of time in the therapeutic INR range was 61.6% for patients receiving genotype-guided dosing and 60.2% for those receiving clinically guided dosing (P = 0.52). There were no significant differences between the two groups for several secondary outcomes. The percentage of time in the therapeutic range during the first 4 weeks after the initiation of treatment in the two groups was 52.8% and 47.5% (P = 0.02), respectively. There were no significant differences with respect to the incidence of bleeding or thromboembolic events. CONCLUSIONS Genotype-guided dosing of acenocoumarol or phenprocoumon did not improve the percentage of time in the therapeutic INR range during the 12 weeks after the initiation of therapy. (Funded by the European Commission Seventh Framework Programme and others; EU-PACT ClinicalTrials.gov numbers, NCT01119261 and NCT01119274.)
- Published
- 2013
16. Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics
- Author
-
Manolopoulos, V.G. Ragia, G. Alevizopoulos, G.
- Subjects
mental disorders - Abstract
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed to treat depression and a broad range of other comorbidities. The increased use of SSRIs in patients with various comorbidities treated with different drugs engenders the risk of pharmacokinetic drug interactions via cytochrome P450 (CYP450) enzymes inhibition. In the present review, we provide an overview of documented clinically significant drug interactions between SSRIs and other drugs co-prescribed in psychiatric patients for the same or other diseases. We further discuss the significance of drug interactions in the era of pharmacogenomics to underline the need for using information on both genotype and drug interactions towards implementing better clinical outcomes through personalized medicine. © 2012 by Walter de Gruyter Berlin Boston 2012.
- Published
- 2012
17. Effectiveness of Acenocoumarol genetic and clinical dosing algorithms in predicting stable dose in the greek cohort of the Eu-pact trial
- Author
-
Manolopoulos, V.G., primary, Ragia, G., additional, Tavridou, A., additional, Kolovou, V., additional, Kolovou, G., additional, Maltezos, E., additional, Tziakas, D., additional, and Konstantinides, S., additional
- Published
- 2015
- Full Text
- View/download PDF
18. Pharmacogenetic profile of lipid response to atorvastatin in children and adolescents with familial Hypercholesterolemia
- Author
-
Manolopoulos, V.G., primary, Drogari, E., additional, Ragia, G., additional, Mollaki, V., additional, Elens, L., additional, and Van Schaik, R.H.N., additional
- Published
- 2015
- Full Text
- View/download PDF
19. The effect of hydrogen sulfide donors on TNF-α induced expression of NADPH subunits in endothelial cells
- Author
-
Giannakopoulou, E., primary, Papapetropoulos, A., additional, Manolopoulos, V.G., additional, and Tavridou, A., additional
- Published
- 2015
- Full Text
- View/download PDF
20. Antiatherosclerotic properties of EP2302, A novel squalene synthase inhibitor, in the cholesterol-fed rabbit
- Author
-
Tavridou, A. Kaklamanis, L. Papalois, A. Kourounakis, A.P. Rekka, E.A. Kourounakis, P.N. Charalambous, A. Manolopoulos, V.G.
- Abstract
EP2302 is a novel nitric oxide donor compound that inhibits squalene synthase. We hypothesized that EP2302 can reduce atherosclerosis in the cholesterol-fed rabbit atherosclerosis model. Animals were fed a high-cholesterol (HC) diet for 4 weeks. Animals subsequently received drug or placebo for 4 (n = 15) or 12 weeks (n = 15) while on HC diet. A third group (n = 16) received drug or placebo for 4 weeks while on regular diet (regression group). No significant differences were observed in circulating lipids among any of the treatment groups at each time point during HC intake. The perimeter and area of the ascending aorta covered by lesions were significantly decreased in animals treated with 2 mg/kg EP2302 for 4 weeks (44% and 42% reduction, respectively). Moreover, a significant decrease in the perimeter of the ascending and descending aorta covered by lesions was observed in animals treated with 2 mg/kg EP2302 for 12 weeks (73% and 44% reduction, respectively) as well as in the regression group (61% and 65% reduction, respectively). Treatment with EP2302 did not cause any toxicity in animal vital organs. We have shown that EP2302 inhibits atherosclerosis in the cholesterol-fed rabbit and therefore may serve as a candidate drug to be tested in humans for atherosclerosis-related disorders. © 2008 by Lippincott Williams & Wilkins.
- Published
- 2008
21. EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit
- Author
-
Tavridou, A. Kaklamanis, L. Papalois, A. Kourounakis, A.P. Rekka, E.A. Kourounakis, P.N. Charalambous, A. Manolopoulos, V.G.
- Abstract
EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide] inhibits squalene synthase and lipid biosynthesis and possesses antioxidant properties. We hypothesized that EP2306 can effectively modify circulating lipids and reduce atherosclerosis in the cholesterol-fed rabbit. Animals were fed a high-cholesterol diet for 4 weeks followed by 4 (phase 1 and 2) or 12 weeks (phase 3) of drug treatment while on high-cholesterol diet. In phase 1, the dose-effect relationship of EP2306 on lipids and atherosclerosis was established, and its most effective dose was determined (2 mg/kg). This dose reduced significantly total cholesterol (512 ± 96 mg/dl before versus 320 ± 124 mg/dl after treatment, p < 0.05) and atherosclerotic lesions compared with control animals. In phase 2, the effects of 2 mg/kg EP2306, 2.5 mg/kg simvastatin, and their combination were assessed. Although no significant effect on lipid parameters was observed, there was a significant reduction (35 ± 5%, p < 0.05) of atherosclerotic lesions in animals treated with EP2306, a similar reduction with simvastatin, and a further reduction (48 ± 7%, p < 0.05) when the two agents were combined. In animals treated for 12 weeks with the drugs (phase 3), only EP2306 significantly reduced atherosclerotic lesions by more than 50%, whereas simvastatin alone or in combination with EP2306 had no effect. Treatment with EP2306 did not adversely affect liver transaminases or cause any histopathological changes on various organs of the animals. In conclusion, we have shown that EP2306 inhibits atherosclerosis in vivo, indicating potential as a novel therapeutic agent for coronary artery disease and other atherosclerosis-related disorders. Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics.
- Published
- 2007
22. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis
- Author
-
Tavridou, A. Kaklamanis, L. Megaritis, G. Kourounakis, A.P. Papalois, A. Roukounas, D. Rekka, E.A. Kourounakis, P.N. Charalambous, A. Manolopoulos, V.G.
- Subjects
lipids (amino acids, peptides, and proteins) - Abstract
We investigated the effects of EP2306 and EP2302, two novel 2-biphenylmorpholine derivatives, on squalene synthase activity in rabbit and human liver microsomes, lipid biosynthesis, low-density lipoprotein (LDL) receptor expression and LDL protein uptake as well as apoB secretion in HepG2 cells. Both EP2306 and EP2302 inhibited squalene synthase activity dose-dependently. In rabbit liver microsomes, the IC50 values were 33 μM for EP2306 and 0.6 μM for EP2302 whereas in human liver microsomes, they were 63 μM for EP2306 and 1 μM for EP2302. Both EP2300 compounds inhibited cholesterol production by HepG2 cells dose dependently with IC 50 values of 13.3 μM for EP2306 and 3 μM for EP2302. Furthermore, both EP2300 compounds and simvastatin significantly reduced triglyceride synthesis and apoB secretion and increased LDL receptor expression and LDL uptake in HepG2 cells. In summary, we have shown that EP2300 compounds are potent inhibitors of squalene synthase activity in rabbit and human liver microsomes and also they are effective inhibitors of cholesterol and triglyceride biosynthesis in HepG2 cells. These results suggest that EP2306 and EP2302 might prove to be useful for lipid-lowering and treatment of atherosclerosis in vivo. © 2006 Elsevier B.V. All rights reserved.
- Published
- 2006
23. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon
- Author
-
Verhoef, T.I. (Talitha), Ragia, G. (Georgia), Boer, A.C. (Anton) de, Barallon, R. (Rita), Kolovou, G. (Genovefa), Konstantinides, S. (Stavros), Cessie, S. (Saskia) le, Maltezos, E. (Efstratios), Meer, F.J.M. (Felix) van der, Redekop, W.K. (Ken), Remkes, P.A.J., Rosendaal, F.R. (Frits), Schie, R.F.M. (Rianne) van, Tavridou, A. (Anna), Tziakas, D. (Dimitrios), Wadelius, M. (Mia), Manolopoulos, V.G. (Vangelis), Maitland-van der Zee, A-H. (Anke-Hilse), Verhoef, T.I. (Talitha), Ragia, G. (Georgia), Boer, A.C. (Anton) de, Barallon, R. (Rita), Kolovou, G. (Genovefa), Konstantinides, S. (Stavros), Cessie, S. (Saskia) le, Maltezos, E. (Efstratios), Meer, F.J.M. (Felix) van der, Redekop, W.K. (Ken), Remkes, P.A.J., Rosendaal, F.R. (Frits), Schie, R.F.M. (Rianne) van, Tavridou, A. (Anna), Tziakas, D. (Dimitrios), Wadelius, M. (Mia), Manolopoulos, V.G. (Vangelis), and Maitland-van der Zee, A-H. (Anke-Hilse)
- Abstract
BACKGROUND: Observational evidence suggests that the use of a genotype-guided dosing algorithm may increase the effectiveness and safety of acenocoumarol and phenprocoumon therapy. METHODS: We conducted two single-blind, randomized trials comparing a genotype-guided dosing algorithm that included clinical variables and genotyping for CYP2C9 and VKORC1 with a dosing algorithm that included only clinical variables, for the initiation of acenocoumarol or phenprocoumon treatment in patients with atrial fibrillation or venous thromboembolism. The primary outcome was the percentage of time in the target range for the international normalized ratio (INR; target range, 2.0 to 3.0) in the 12-week period after the initiation of therapy. Owing to low enrollment, the two trials were combined for analysis. The primary outcome was assessed in patients who remained in the trial for at least 10 weeks. RESULTS: A total of 548 patients were enrolled (273 patients in the genotype-guided group and 275 in the control group). The follow-up was at least 10 weeks for 239 patients in the genotype-guided group and 245 in the control group. The percentage of time in the therapeutic INR range was 61.6% for patients receiving genotype-guided dosing and 60.2% for those receiving clinically guided dosing (P = 0.52). There were no significant differences between the two groups for several secondary outcomes. The percentage of time in the therapeutic range during the first 4 weeks after the initiation of treatment in the two groups was 52.8% and 47.5% (P = 0.02), respectively. There were no significant differences with respect to the incidence of bleeding or thromboembolic events. CONCLUSIONS: Genotype-guided dosing of acenocoumarol or phenprocoumon did not improve the percentage of time in the therapeutic INR range during the 12 weeks after the initiation of therapy. Copyright
- Published
- 2013
- Full Text
- View/download PDF
24. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
- Author
-
Schie, R.F.M. (Rianne) van, Wadelius, M. (Mia), Kamali, F. (Farhad), Daly, A.K. (Ann), Manolopoulos, V.G. (Vangelis), Boer, A.C. (Anton) de, Barallon, R. (Rita), Verhoef, T.I. (Talitha), Kirchheiner, J. (Julia), Haschke-Becher, E. (Elisabeth), Briz, M. (Montserrat), Rosendaal, F.R. (Frits), Redekop, W.K. (Ken), Pirmohamed, M. (Munir), Maitland-van der Zee, A-H. (Anke-Hilse), Schie, R.F.M. (Rianne) van, Wadelius, M. (Mia), Kamali, F. (Farhad), Daly, A.K. (Ann), Manolopoulos, V.G. (Vangelis), Boer, A.C. (Anton) de, Barallon, R. (Rita), Verhoef, T.I. (Talitha), Kirchheiner, J. (Julia), Haschke-Becher, E. (Elisabeth), Briz, M. (Montserrat), Rosendaal, F.R. (Frits), Redekop, W.K. (Ken), Pirmohamed, M. (Munir), and Maitland-van der Zee, A-H. (Anke-Hilse)
- Abstract
The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for about 40% of the interindividual
- Published
- 2009
- Full Text
- View/download PDF
25. Dosing algorithms for vitamin K antagonists across VKORC1and CYP2C9genotypes
- Author
-
Baranova, E.V., Verhoef, T.I., Ragia, G., le Cessie, S., Asselbergs, F.W., de Boer, A., Manolopoulos, V.G., Maitland‐van der Zee, A.H., Barallon, R., Daly, A., Kamili, F., Redekop, K., Pirmohamed, M., Rosendaal, F.R., and Wadelius, M.
- Abstract
Unlabelled Boxce:textbox-body/
- Published
- 2017
- Full Text
- View/download PDF
26. 645 MONOCYTE CHEMOATTRACTANT PROTEIN-1 -2518A>G GENE POLYMORHISM AND THE RISK OF ISCHAEMIC STROKE IN CAUCASIAN SUBJECTS
- Author
-
Tavridou, A., primary, Giannakopoulou, E., additional, Ragia, G., additional, Marousi, S., additional, Ellul, J., additional, and Manolopoulos, V.G., additional
- Published
- 2011
- Full Text
- View/download PDF
27. DETERMINANTS OF CAROTID INTIMA-MEDIA THICKNESS IN BETA-THALASSEMIA MAJOR
- Author
-
Tavridou, A., primary, Vryonidou, A., additional, Karapostolakis, G., additional, Giannoulakos, N., additional, Phenekos, C., additional, and Manolopoulos, V.G., additional
- Published
- 2008
- Full Text
- View/download PDF
28. INFLUENCE OF ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE POLYMORPHISMS (-786T > C AND 894G > T) IN GREEK PATIENTS WITH CORONARY ARTERY DISEASE
- Author
-
Ragia, G., primary, Tavridou, A., additional, Nikolaidis, E., additional, Arvanitidis, K., additional, Bougioukas, G., additional, and Manolopoulos, V.G., additional
- Published
- 2008
- Full Text
- View/download PDF
29. PO23-752 EFFECT OF SIMVASTATIN TREATMENT ON CIRCULATING OXIDIZED LOW-DENSITY LIPOPROTEIN LEVELS IN DIFFERENT TYPES OF HYPERLIPIDEMIA
- Author
-
Tavridou, A., primary, Efthimiadis, A., additional, Efthimiadis, I., additional, Paschalidou, H., additional, Raptopoulou-Gigi, M., additional, and Manolopoulos, V.G., additional
- Published
- 2007
- Full Text
- View/download PDF
30. Mo-P5:370 Oxidized low-density lipoprotein in beta-thalassemia major
- Author
-
Tavridou, A., primary, Stakos, D., additional, Vryonidou, A., additional, Tsigalou, C., additional, Kambouromiti, G., additional, Phenekos, C., additional, and Manolopoulos, V.G., additional
- Published
- 2006
- Full Text
- View/download PDF
31. Th-P16:292 Effect f ezetimibe monotheraphy on circulating oxidized low-density lipoprotein and cell adhesion molecules
- Author
-
Tavridou, A., primary, Efthimiadis, A., additional, Efthimiadis, I., additional, Paschalidou, H., additional, Raptopoulou-Gigi, M., additional, and Manolopoulos, V.G., additional
- Published
- 2006
- Full Text
- View/download PDF
32. W12-P-074 Inhibition of squalene synthase activity and lipid biosynthesis by EP2306 and EP2302, two novel 2-biphenylmorpholine compounds
- Author
-
Tavridou, A., primary, Kaklamanis, L., additional, Megaritis, G., additional, and Manolopoulos, V.G., additional
- Published
- 2005
- Full Text
- View/download PDF
33. Characterisation of explanted endothelial cells from mouse aorta: electrophysiology and Ca 2+ signalling
- Author
-
Suh, S.H., primary, Vennekens, R., additional, Manolopoulos, V.G., additional, Freichel, M., additional, Schweig, U., additional, Prenen, J., additional, Flockerzi, V., additional, Droogmans, G., additional, and Nilius, B., additional
- Published
- 1999
- Full Text
- View/download PDF
34. Expression patterns of sarco/endoplasmic reticulum Ca2+-ATPase and inositol 1,4,5-trisphosphate receptor isoforms in vascular endothelial cells
- Author
-
Mountian, I., primary, Manolopoulos, V.G., additional, Smedt, H.De, additional, Parys, J.B., additional, Missiaen, L., additional, and Wuytack, F., additional
- Published
- 1999
- Full Text
- View/download PDF
35. Adenylyl Cyclase Isoforms Are Differentially Expressed in Primary Cultures of Endothelial Cells and Whole Tissue-Homogenates from Various Rat Tissues
- Author
-
Manolopoulos, V.G., primary, Liu, J.D., additional, Unsworth, B.R., additional, and Lelkes, P.I., additional
- Published
- 1995
- Full Text
- View/download PDF
36. Cyclic Strain and Forskolin Differentially Induce cAMP Production in Phenotypically Diverse Endothelial Cells
- Author
-
Manolopoulos, V.G., primary and Lelkes, P.I., additional
- Published
- 1993
- Full Text
- View/download PDF
37. Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD.
- Author
-
Manolopoulos VG and Ragia G
- Subjects
- Humans, Animals, Antimetabolites, Antineoplastic toxicity, Antimetabolites, Antineoplastic adverse effects, Fluorouracil toxicity, Fluorouracil adverse effects, Epigenesis, Genetic drug effects, Polymorphism, Genetic, Pyrimidines toxicity, Dihydrouracil Dehydrogenase (NADP) genetics, Dihydrouracil Dehydrogenase (NADP) metabolism
- Abstract
Background: Fluoropyrimidine-induced toxicity is a main limitation of therapy. Currently, polymorphisms in the DPYD gene, which encodes the 5-FU activation enzyme dihydropyrimidine dehydrogenase (DPD), are used to adjust the dosage and prevent toxicity. Despite the predictive value of DPYD genotyping, a great proportion of fluoropyrimidine toxicity cannot be solely explained by DPYD variations., Objective: We herein summarize additional sources of DPD enzyme activity variability, spanning from epigenetic regulation of DPYD expression, factors potentially inducing protein modifications, as well as drug-enzyme interactions that contribute to fluoropyrimidine toxicity., Results: While seminal in vitro studies provided evidence that DPYD promoter methylation downregulates DPD expression, the association of DPYD methylation with fluoropyrimidine toxicity was not replicated in clinical studies. Different non-coding RNA molecules, such as microRNA, piwi-RNAs, circular-RNAs and long non-coding RNAs, are involved in post-transcriptional DPYD regulation. DPD protein modifications and environmental factors affecting enzyme activity may also add a proportion to the pooled variability of DPD enzyme activity. Lastly, DPD-drug interactions are common in therapeutics, with the most well-characterized paradigm the withdrawal of sorivudine due to fluoropyrimidine toxicity deaths in 5-FU treated cancer patients; a mechanism involving DPD severe inhibition., Conclusions: DPYD polymorphisms are the main source of DPD variability. A study on DPYD epigenetics (both transcriptionally and post-transcriptionally) holds promise to provide insights into molecular pathways of fluoropyrimidine toxicity. Additional post-translational DPD modifications, as well as DPD inhibition by other drugs, may explain a proportion of enzyme activity variability. Therefore, there is still a lot we can learn about the DPYD/DPD fluoropyrimidine-induced toxicity machinery., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
38. L. plantarum UBLP-40 Versus the Combined Formula of L. rhamnosus UBLP-58 and B. longum UBBL-64 in Excisional Wound Healing: A Cellular Perspective.
- Author
-
Moysidis, Moysis, Chorti, Angeliki, Cheva, Angeliki, Abba Deka, Ioanna, Tzikos, Georgios, Kosmidis, Christoforos, Koutelidakis, Ioannis, Tsetis, Joulia K., Papavramidis, Theodossis, and Kotzampassi, Katerina
- Abstract
Introduction: The utilization of probiotics in enhancing the active healing of skin wounds represents a burgeoning trend in contemporary medicine. Previous research has extensively explored wound healing mechanisms involving the strains of Lactiplantibacillus plantarum, Lacticaseibacillus rhamnosus, and Bifidobacterium longum. This study seeks to compare and interpret cellular findings derived from immunohistochemical and pathological applications. Methods: Three groups (the control, Lactiplantibacillus plantarum (RO1) group, and Lacticaseibacillus rhamnosus and Bifidobacterium longum (PRO2) group) underwent histological analysis, and microscopic cell counting were employed, offering insights into dynamic changes among neutrophils, lymphocytes, plasmacytes, mast cells, fibroblasts, and newly formed vessels across distinct treatment groups and temporal intervals. Results: The neutrophil count was found to be elevated in PRO2 on day 2, while the same group resulted in the highest decline on day 15. The number of fibroblasts peaked on day 4 for the PRO1 group, compared to the other two groups, which peaked on day 8. The lymphocyte count was the highest in the control group, while they peaked on day 4 in PRO2. The mast cells and plasmacytes were variable and sparse among all groups and time frames. Neovascularization was promoted by PRO1 and PRO2 groups on day 4 and remained high on day 8 for PRO2. Conclusions: Probiotic strains can be beneficial to the human population and in assisting skin wound healing, each strain working differently and more effectively in different healing phases. Thus, a combined formula containing different probiotics to modulate various healing phases is desirable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. MIR27A rs895819 CC Genotype Severely Reduces miR-27a Plasma Expression Levels.
- Author
-
Ragia, Georgia, Pallikarou, Myria, Michou, Chrysoula, and Manolopoulos, Vangelis G.
- Abstract
Background/Objectives: MIR27A rs895819 polymorphism has emerged as a potential additional pharmacogenomic marker of fluoropyrimidine response. Current evidence on its potential effect on miR-27a expression, which represses DPD activity, leading to DPD deficiency and increased fluoropyrimidine-associated toxicity risk, is scarce and inconsistent. We have analyzed the effect of MIR27A rs895819 polymorphism on miR-27a-3p plasma expression levels under different models of inheritance to contribute further evidence on its plausible biological role in miR-27a expression. Methods: A total of 59 individuals with no medical history of cancer were included in this study. MIR27A rs895819 genotyping and miR-27a-3p expression were analyzed by using predesigned TaqMan assays. Results: The frequency of TT, TC, and CC genotypes was present at a prevalence of 50.8%, 44.1%, and 5.1%, respectively. Individuals carrying the CC genotype presented with decreased miR-27a-3p expression (0.422 fold-change versus TT, p = 0.041; 0.461 fold-change versus TC, p = 0.064), whereas no differences were present between TT and TC individuals (1.092 fold-change, p = 0.718). miR-27a-3p expression was decreased in CC individuals under a recessive model of inheritance (0.440 fold-change, p = 0.047). No differences were found in dominant (TT vs. TC+CC, 0.845 fold-change, p = 0.471) or over dominant (TT+CC vs. TC, 0.990 fold-change, p = 0.996) models of inheritance. Conclusions: MIR27A rs895819CC genotype leads to severely reduced miR-27a-3p expression in plasma. Further study of this association is warranted in cancer patients to apply MIR27A genotyping in therapeutics to identify fluoropyrimidine-treated patients who are at a decreased risk of experiencing fluoropyrimidine-induced severe toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Characterisation of explanted endothelial cells from mouse aorta: electrophysiology and Ca2+ signalling.
- Author
-
Suh, S.H., Vennekens, R., Manolopoulos, V.G., Freichel, M., Schweig, U., Prenen, J., Flockerzi, V., Droogmans, G., and Nilius, B.
- Abstract
We describe here the isolation and primary culture of endothelial cells from mouse aorta ("primary explant technique"). These cells provide an excellent model for functional studies in transgenic mice. The primary explant method delivers cells that grow out from small pieces of mouse aorta placed on Matrigel enriched with endothelial growth factors. Cells can be studied on the Matrigel after removing the pieces of aorta or after passages by using dispase and reseeding the cells on gelatine-coated cover-slips. Cells on Matrigel or from the first and second passages were characterised using the combined patch-clamp and fura-2 fluorescence methods. Cells had a mean membrane resting potential of –19±3 mV ( n=21), a membrane capacitance of 49±5 pF ( n=37) and a resting cytosolic free [Ca
2+ ] ([Ca2+ ]i ) of 103±8 nM ( n=30). Adenosine 5'-triphosphate (ATP), acetylcholine and bradykinin, but not histamine, induced fast release of intracellular Ca2+ followed by a sustained rise in [Ca2+ ]i . Oscillations in [Ca2+ ]i were observed at lower agonist concentrations. In nearly all cells (93%, n=30), these agonists activated charybdotoxin-sensitive, Ca2+ -activated K+ channels and induced hyperpolarisation. In 84% of the cells ( n=32), an increase in [Ca2+ ]i also activated strongly outwards-rectifying Cl– channels. These activated slowly at positive potentials and inactivated rapidly at negative potentials. Increasing [Ca2+ ]i to 1 µM activated a non-selective cation channel in 86% of the cells ( n=28). Each tested cell responded to a challenge with hypotonic solution by activating a Cl– current that was modestly outwards rectifying and inactivated at positive potentials. This current is similar to the well-described swelling-activated current through volume-regulated anion channels (VRAC) in endothelial cells. However, its activation is slower, its inactivation faster and the current density lower than in cultured endothelial cells. It is concluded that the primary explant technique provides a reliable cell model for studying mouse vascular endothelial cell function. [ABSTRACT FROM AUTHOR]- Published
- 1999
- Full Text
- View/download PDF
41. Diallyl Trisulfide and Cardiovascular Health: Evidence and Potential Molecular Mechanisms.
- Author
-
Novakovic, Jovana, Muric, Maja, Bradic, Jovana, Ramenskaya, Galina, Jakovljevic, Vladimir, and Jeremic, Nevena
- Subjects
HEART diseases ,HYDROGEN sulfide ,DISEASE incidence ,RESEARCH personnel ,MEDICAL research ,GARLIC - Abstract
Traditionally, garlic has a valuable role in preventing and reducing the incidence of many diseases and pathophysiological disorders. Consequently, some researchers have focused on the beneficial cardiovascular properties of diallyl trisulfide (DATS), the most potent polysulfide isolated from garlic. Therefore, in this review, we collected the available data on DATS, its biochemical synthesis, metabolism and pharmacokinetics, and gathered the current knowledge and the role of DATS in cardiovascular diseases. Overall, this review summarizes the cardioprotective effects of DATS and brings together all previous findings on its protective molecular mechanisms, which are mainly based on the potent anti-apoptotic, anti-inflammatory, and antioxidant potential of this polysulfide. Our review is an important cornerstone for further basic and clinical research on DATS as a new therapeutic agent for the treatment of numerous heart diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. How Do Socio-Demographic Factors, Health Status, and Knowledge Influence the Acceptability of Probiotics Products in Hong Kong?
- Author
-
Xu, Zilin, Wu, Nan, and Chan, Shun Wan
- Subjects
DIETARY supplements ,HEALTH literacy ,SOCIODEMOGRAPHIC factors ,CONSUMER preferences ,PRODUCT acceptance - Abstract
In recent years, due to growing interest in gut health, the potential benefits of probiotics on the gut have received much attention. Probiotics, now readily available in both dietary supplements and a variety of foods, have become a focal point of consumer health choices. This study aims to explore the impact of consumer-related factors, including socio-demographic profiles, health status, and probiotics knowledge, on the acceptance of probiotics products in Hong Kong. A total of 385 participants engaged in a survey, providing data for an in-depth analysis of how these factors influence attitudes toward probiotics. Findings revealed a general confidence in the safety of probiotics products among respondents; however, there was a noticeable gap in probiotics understanding. The study highlighted a correlation between probiotics knowledge and specific socio-demographic attributes, with higher educational attainment positively linked to greater probiotics awareness. Furthermore, the research indicated that women exhibit higher health consciousness and a greater propensity for probiotics consumption compared to men. Consequently, promoting enhanced probiotics education and fostering increased health awareness are crucial steps to prevent the misuse of probiotics and optimize health outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Receptors Involved in COVID-19-Related Anosmia: An Update on the Pathophysiology and the Mechanistic Aspects.
- Author
-
Al-Saigh, Noor N., Harb, Amani A., and Abdalla, Shtaywy
- Subjects
COVID-19 ,ANGIOTENSIN converting enzyme ,COVID-19 pandemic ,TRPV cation channels ,OLFACTORY perception ,OLFACTORY receptors ,SODIUM channels - Abstract
Olfactory perception is an important physiological function for human well-being and health. Loss of olfaction, or anosmia, caused by viral infections such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has received considerable attention, especially in persistent cases that take a long time to recover. This review discusses the integration of different components of the olfactory epithelium to serve as a structural and functional unit and explores how they are affected during viral infections, leading to the development of olfactory dysfunction. The review mainly focused on the role of receptors mediating the disruption of olfactory signal transduction pathways such as angiotensin converting enzyme 2 (ACE2), transmembrane protease serine type 2 (TMPRSS2), neuropilin 1 (NRP1), basigin (CD147), olfactory, transient receptor potential vanilloid 1 (TRPV1), purinergic, and interferon gamma receptors. Furthermore, the compromised function of the epithelial sodium channel (ENaC) induced by SARS-CoV-2 infection and its contribution to olfactory dysfunction are also discussed. Collectively, this review provides fundamental information about the many types of receptors that may modulate olfaction and participate in olfactory dysfunction. It will help to understand the underlying pathophysiology of virus-induced anosmia, which may help in finding and designing effective therapies targeting molecules involved in viral invasion and olfaction. To the best of our knowledge, this is the only review that covered all the receptors potentially involved in, or mediating, the disruption of olfactory signal transduction pathways during COVID-19 infection. This wide and complex spectrum of receptors that mediates the pathophysiology of olfactory dysfunction reflects the many ways in which anosmia can be therapeutically managed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy.
- Author
-
Ikonnikova, Anna, Fedorinov, Denis, Gryadunov, Dmitry, Heydarov, Rustam, Lyadova, Marina, Moskalenko, Alexey, Mikhailovich, Vladimir, Emelyanova, Marina, and Lyadov, Vladimir
- Subjects
DIHYDROPYRIMIDINE dehydrogenase ,GENETIC variation ,GENETIC polymorphisms ,GASTROINTESTINAL tumors ,NEUTROPENIA ,PHARMACOGENOMICS - Abstract
To reduce severe fluoropyrimidine-related toxicity, pharmacogenetic guidelines recommend a dose reduction for carriers of four high-risk variants in the DPYD gene (*2A, *13, c.2846A>T, HapB3). The polymorphism in the MIR27A gene has been shown to enhance the predictive value of these variants. Our study aimed to explore whether rs895819 in the MIR27A gene modifies the effect of five common DPYD variants: c.1129-5923C>G (rs75017182, HapB3), c.2194G>A (rs1801160, *6), c.1601G>A (rs1801158, *4), c.496A>G (rs2297595), and c.85T>C (rs1801265, *9A). The study included 370 Caucasian patients with gastrointestinal tumors who received fluoropyrimidine-containing chemotherapy. Genotyping was performed using high-resolution melting analysis. The DPYD*6 allele was associated with overall severe toxicity and neutropenia with an increased risk particularly pronounced in patients carrying the MIR27A variant. All carriers of DPYD*6 exhibited an association with asthenia regardless of their MIR27A status. The increased risk of neutropenia in patients with c.496G was only evident in those co-carrying the MIR27A variant. DPYD*4 was also significantly linked to neutropenia risk in co-carriers of the MIR27A variant. Thus, we have demonstrated the predictive value of the *6, *4, and c.496G alleles of the DPYD gene, considering the modifying effect of the MIR27A polymorphism. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase—Bridging Basic Research to Clinical Findings.
- Author
-
Muric, Maja, Nikolic, Marina, Todorovic, Andreja, Jakovljevic, Vladimir, and Vucicevic, Ksenija
- Subjects
ANTICOAGULANTS ,THROMBOSIS ,CARDIOVASCULAR system ,ORAL medication ,MEDICAL research ,PLASMIN - Abstract
The use of non-vitamin K antagonist oral anticoagulants (NOACs) has brought a significant progress in the management of cardiovascular diseases, considered clinically superior to vitamin K antagonists (VKAs) particularly in the prevention and treatment of thromboembolic events. In addition, numerous advantages such as fixed dosing, lack of laboratory monitoring, and fewer food and drug-to-drug interactions make the use of NOACs superior to VKAs. While NOACs are synthetic drugs prescribed for specific conditions, nattokinase (NK) is a natural enzyme derived from food that has potential health benefits. Various experimental and clinical studies reported the positive effects of NK on the circulatory system, including the thinning of blood and the dissolution of blood clots. This enzyme showed not only fibrinolytic activity due to its ability to degrade fibrin, but also an affinity as a substrate for plasmin. Recent studies have shown that NK has additional cardioprotective effects, such as antihypertensive and anti-atherosclerotic effects. In this narrative review, we presented the cardioprotective properties of two different approaches that go beyond anticoagulation: NOACs and NK. By combining evidence from basic research with clinical findings, we aim to elucidate the comparative cardioprotective efficacy of these interventions and highlight their respective roles in modern cardiovascular care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Impact of Serotonin Transporter Absence on Brain Insulin Receptor Expression, Plasma Metabolome Changes, and ADHD-like Behavior in Mice fed a Western Diet.
- Author
-
Anthony, Daniel C., Probert, Fay, Gorlova, Anna, Hebert, Jenna, Radford-Smith, Daniel, Nefedova, Zlata, Umriukhin, Aleksei, Nedorubov, Andrey, Cespuglio, Raymond, Shulgin, Boris, Lyundup, Aleksey, Lesch, Klaus Peter, and Strekalova, Tatyana
- Subjects
NUCLEAR magnetic resonance spectroscopy ,INSULIN receptors ,WESTERN diet ,SEROTONIN transporters ,PLASMA spectroscopy - Abstract
The impaired function of the serotonin transporter (SERT) in humans has been linked to a higher risk of obesity and type 2 diabetes, especially as people age. Consuming a "Western diet" (WD), which is high in saturated fats, cholesterol, and sugars, can induce metabolic syndrome. Previous research indicated that mice carrying a targeted inactivation of the Sert gene (knockout, KO) and fed a WD display significant metabolic disturbances and behaviors reminiscent of ADHD. These abnormalities might be mediated via a dysfunction in insulin receptor (IR) signaling, which is also associated with adult ADHD. However, the impact of Sert deficiency on IR signaling and systemic metabolic changes has not been thoroughly explored. In this study, we conducted a detailed analysis of locomotor behavior in wild-type (WT) and KO mice fed a WD or control diet. We investigated changes in the blood metabolome and examined, via PCR, the expression of insulin receptor A and B isoforms and key regulators of their function in the brain. Twelve-month-old KO mice and their WT littermates were fed a WD for three weeks. Nuclear magnetic resonance spectroscopy analysis of plasma samples showed that KO mice on a WD had higher levels of lipids and lipoproteins and lower levels of glucose, lactate, alanine, valine, and isoleucine compared to other groups. SERT-KO mice on the control diet exhibited increased brain levels of both IR A and B isoforms, accompanied by a modest increase in the negative regulator ENPP. The KO mice also displayed anxiety-like behavior and reduced exploratory activity in an open field test. However, when the KO animals were fed a WD, the aberrant expression levels of IR isoforms in the KO mice and locomotor behavior were ameliorated indicating a complex interaction between genetic and dietary factors that might contribute to ADHD-like symptoms. Overall, our findings suggest that the lack of Sert leads to a unique metabolic phenotype in aged mice, characterized by dysregulated IR-related pathways. These changes are exacerbated by WD in the blood metabolome and are associated with behavioral abnormalities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.
- Author
-
Hossam Abdelmonem, Basma, Abdelaal, Noha M., Anwer, Eman K. E., Rashwan, Alaa A., Hussein, Mohamed Ali, Ahmed, Yasmin F., Khashana, Rana, Hanna, Mireille M., and Abdelnaser, Anwar
- Subjects
VITAMIN D metabolism ,LIPID metabolism ,ENZYME metabolism ,BILE acids ,CYTOCHROME P-450 ,DRUG metabolism - Abstract
Cytochrome P450 (CYP450) is a group of enzymes that play an essential role in Phase I metabolism, with 57 functional genes classified into 18 families in the human genome, of which the CYP1, CYP2, and CYP3 families are prominent. Beyond drug metabolism, CYP enzymes metabolize endogenous compounds such as lipids, proteins, and hormones to maintain physiological homeostasis. Thus, dysregulation of CYP450 enzymes can lead to different endocrine disorders. Moreover, CYP450 enzymes significantly contribute to fatty acid metabolism, cholesterol synthesis, and bile acid biosynthesis, impacting cellular physiology and disease pathogenesis. Their diverse functions emphasize their therapeutic potential in managing hypercholesterolemia and neurodegenerative diseases. Additionally, CYP450 enzymes are implicated in the onset and development of illnesses such as cancer, influencing chemotherapy outcomes. Assessment of CYP450 enzyme expression and activity aids in evaluating liver health state and differentiating between liver diseases, guiding therapeutic decisions, and optimizing drug efficacy. Understanding the roles of CYP450 enzymes and the clinical effect of their genetic polymorphisms is crucial for developing personalized therapeutic strategies and enhancing drug responses in diverse patient populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Vitamin K for Vascular Calcification in Kidney Patients: Still Alive and Kicking, but Still a Lot to Learn.
- Author
-
Neofytou, Ioannis Eleftherios, Stamou, Aikaterini, Demopoulos, Antonia, Roumeliotis, Stefanos, Zebekakis, Pantelis, Liakopoulos, Vassilios, Stamellou, Eleni, and Dounousi, Evangelia
- Abstract
Patients with chronic kidney disease (CKD) suffer disproportionately from a high burden of cardiovascular disease, which, despite recent scientific advances, remains partly understood. Vascular calcification (VC) is the result of an ongoing process of misplaced calcium in the inner and medial layers of the arteries, which has emerged as a critical contributor to cardiovascular events in CKD. Beyond its established role in blood clotting and bone health, vitamin K appears crucial in regulating VC via vitamin K-dependent proteins (VKDPs). Among these, the matrix Gla protein (MGP) serves as both a potent inhibitor of VC and a valuable biomarker (in its inactive form) for reflecting circulating vitamin K levels. CKD patients, especially in advanced stages, often present with vitamin K deficiency due to dietary restrictions, medications, and impaired intestinal absorption in the uremic environment. Epidemiological studies confirm a strong association between vitamin K levels, inactive MGP, and increased CVD risk across CKD stages. Based on the promising results of pre-clinical data, an increasing number of clinical trials have investigated the potential benefits of vitamin K supplementation to prevent, delay, or even reverse VC, but the results have remained inconsistent. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Pleiotropic Effects of Direct Oral Anticoagulants in Chronic Heart Failure and Atrial Fibrillation: Machine Learning Analysis.
- Author
-
Mele, Marco, Mele, Antonietta, Imbrici, Paola, Samarelli, Francesco, Purgatorio, Rosa, Dinoi, Giorgia, Correale, Michele, Nicolotti, Orazio, De Luca, Annamaria, Brunetti, Natale Daniele, Liantonio, Antonella, and Amoroso, Nicola
- Subjects
APIXABAN ,ANTICOAGULANTS ,ORAL medication ,ATRIAL fibrillation ,HEART failure ,WARFARIN ,DATABASES - Abstract
Oral anticoagulant therapy (OAT) for managing atrial fibrillation (AF) encompasses vitamin K antagonists (VKAs, such as warfarin), which was the mainstay of anticoagulation therapy before 2010, and direct-acting oral anticoagulants (DOACs, namely dabigatran etexilate, rivaroxaban, apixaban, edoxaban), approved for the prevention of AF stroke over the last thirteen years. Due to the lower risk of major bleeding associated with DOACs, anticoagulant switching is a common practice in AF patients. Nevertheless, there are issues related to OAT switching that still need to be fully understood, especially for patients in whom AF and heart failure (HF) coexist. Herein, the effective impact of the therapeutic switching from warfarin to DOACs in HF patients with AF, in terms of cardiac remodeling, clinical status, endothelial function and inflammatory biomarkers, was assessed by a machine learning (ML) analysis of a clinical database, which ultimately shed light on the real positive and pleiotropic effects mediated by DOACs in addition to their anticoagulant activity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Anti-SARS-CoV-2 Viral Activity of Sweet Potato Trypsin Inhibitor via Downregulation of TMPRSS2 Activity and ACE2 Expression In Vitro and In Vivo.
- Author
-
Jiang, Wen-Ping, Deng, Jeng-Shyan, Yu, Chia-Chen, Lin, Jaung-Geng, and Huang, Guan-Jhong
- Subjects
SARS-CoV-2 ,TRYPSIN inhibitors ,SWEET potatoes ,CELL receptors ,ANGIOTENSIN converting enzyme - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. Known as COVID-19, it has affected billions of people worldwide, claiming millions of lives and posing a continuing threat to humanity. This is considered one of the most extensive pandemics ever recorded in human history, causing significant losses to both life and economies globally. However, the available evidence is currently insufficient to establish the effectiveness and safety of antiviral drugs or vaccines. The entry of the virus into host cells involves binding to angiotensin-converting enzyme 2 (ACE2), a cell surface receptor, via its spike protein. Meanwhile, transmembrane protease serine 2 (TMPRSS2), a host surface protease, cleaves and activates the virus's S protein, thus promoting viral infection. Plant protease inhibitors play a crucial role in protecting plants against insects and/or microorganisms. The major storage proteins in sweet potato roots include sweet potato trypsin inhibitor (SWTI), which accounts for approximately 60% of the total water-soluble protein and has been found to possess a variety of health-promoting properties, including antioxidant, anti-inflammatory, ACE-inhibitory, and anticancer functions. Our study found that SWTI caused a significant reduction in the expression of the ACE2 and TMPRSS2 proteins, without any adverse effects on cells. Therefore, our findings suggest that the ACE2 and TMPRSS2 axis can be targeted via SWTI to potentially inhibit SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.